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Response 
To the Editor: 
We appreciate Dr. Kramer's comments and while 
we agree with many of his general assertions, we feel 
that he has mixed up several related but distinct is- 
sues: (1) change in positive and negative symptoms 
with neurolepfic treatment in the acute phase of the 
illness (this was the question addressed in our present 
study) (2) the measurement of negative symptoms 
and their delineation from phenomena such as depres- 
sion and EPS; (3) the relationship of cholinergic hy- 
peractivity to negative symptoms and the possible 
role of anticholinergics in their treatment. 
In our study, we observed that negative symptoms 
improved in tandem with positive symptoms. Factors 
such as EPS and akinetic depression did not confound 
this observation as baseline negative symptom ratings 
(from which improvement was measured) were per- 
formed when patients were drag-free for a minimum 
of 2 weeks and both psychotropic-n~ve and previ- 
ously treated patients showed this same pattern of 
improvement. Despite the phenomenological overlap 
between depression and negative symptoms, recent 
studies (including our own, Liberzon et al 1990), 
indicate that these phenomena can be distinctly mea- 
sured. With regard to positive symptoms, most ex- 
perts consider positive and negative to be distinct 
symptom dimensions, which may be related at some 
phases of the illness. Our finding do sugges! Lhat 
psychotic-phasic negative symptoms may differ from 
deficit-enduring negative symptoms with regard to 
neuroleptic-responsiveness and covariance wltb pos- 
itive symptoms, but to further infer that the former 
are not "true negative symptoms" would be premature 
(Andreasen 1999; Tandon and Greden 1990). 
The implications of our findings are less clear. 
Several mechanisms (including concomitant ~ c -  
tion in dopaminergic and cholinergic activity) ~ be 
invoked to explain these findings. Thus, although 
these findings would be consistent with ~ ~ I  of 
concomitant increases in dopaminergic ~ cholm- 
ergic activity in the psychotic ~ of schizophrenic 
illness (related to positive ~ negative symptoms, 
respectively), other explanatiom are plausible as well. 
We would like to underscore the point that ~ do- 
paminergic/cholinergic model ?nd the implicati~ of 
cholinergic hyperactivity in the production of nega- 
tive symptoms are hypotheses to be tested, ~ the 
study suggested by Dr. K.,mner might be one way to 
test it. 
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Epstein-Barr Virus Antibodies and 
Severity of Depreasion 
To the Editor: 
While laboratory evidence of impaired cellular 
immune function has been reported in patients with 
affective disorders (Kronfol et al 1983, 1985; Schlei- 
fer et al 1984; Syvalahti et al 1985; Albrecht et al 
1985; Irwin and Gillin 1987), this has not been linked 
to an increased risk of clinical infection in these pa- 
tients. Antibodies reactive with Epstein-Ban" Viru.': 
(EBV)-associated antigens are present in most adults, 
indicating endemic latent infection with this patho- 
gen. Elevated titers of these antibodies are seen in a 
variety of ~unocompromised  states, presumably 
indicating persistent active or reactivated infection as 
